New York Times Feed


    Rohingya refugee camps on the brink of a 'health disaster': MSF September 23, 2017

    Bangladesh's refugee camps are on the brink of a 'public health disaster,' Doctors Without Borders (MSF) warned Friday.

    It said filthy water and faeces flow through shanties bursting with Rohingya Muslims who have fled violence in Myanmar.

    Nearly 430,000 Rohingya have poured into Bangladesh, seeking refuge from an army-led crackdown across the border in Myanmar's Rakhine state, which the UN has described as 'ethnic cleansing'.

    'One small event could lead"...

    Continue Reading >
    IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to ‘listen for the sounds of IPF’September 18, 2017

    (AETOS Wire)-- IPF is a progressive and debilitating disease which causes continual and irreversible damage to the lungs.1 Early diagnosis is vital because without appropriate medical intervention, the opportunity to slow disease progression is lost. However, diagnosis can be challenging.1,2This year for IPF World Week (16-24 September), Boehringer Ingelheim is raising awareness of ‘the sounds of IPF’ helping physicians recognise the velcro-like crackle which can be heard"...

    Continue Reading >
    CHMP positive opinion to include RE-CIRCUIT® data for atrial fibrillation patients undergoing catheter ablation in Pradaxa® Summary of Product CharacteristicsSeptember 18, 2017

    • The CHMP of the EMA has issued a positive opinion for an update of the Summary of Product Characteristics (SmPC) for Pradaxa® (dabigatran etexilate)
    • The CHMP recommends to include data showing that catheter ablation can be conducted in patients on 150 mg twice daily Pradaxa®, without interrupting Pradaxa® treatment
    • In RE-CIRCUIT®, uninterrupted Pradaxa® showed less major bleeding than warfarin in atrial fibrillation patients undergoing catheter ablation


    Continue Reading >
    42 patients get free surgeries, check-ups from JOHUD Goodwill campaign September 17, 2017

    Forty-two patients, from various parts of the Kingdom, have underwent free surgeries and check-ups on previous surgeries in several private hospitals in Amman, in cooperation with the Jordanian Hashemite Fund for Human Development’s (JOHUD) Goodwill Campaign, the Jordan News Agency, Petra, reported on Saturday.

    The campaign’s medical programme is the only organisation that presents such “advanced” medical services to underprivileged"...

    Continue Reading >
    Bioventus Announces First Patients Enrolled in BONES Study for EXOGEN®September 17, 2017

    (AETOS Wire) -- Bioventus, a global leader in orthobiologics, today announced the first patients have been enrolled in its BONES (Bioventus Observational Non-interventional EXOGEN Studies) clinical development program. BONES includes three observational, non-interventional, direct-to-patient studies designed to collect real world data on the use of the EXOGEN Ultrasound Bone Healing System. EXOGEN uses safe, effective low-intensity pulsed ultrasound (LIPUS) to help stimulate the body’s natural bone healing process. The BONES studies will compare the incidence of fracture nonunions in patients utilizing EXOGEN with patients from a national health insurance claims database who received standard of care alone. The studies will include long and small bones of upper and lower extremities and the unique design of BONES was discussed with FDA during its development. Its primary endpoint is......

    Continue Reading >
    Boehringer Ingelheim receives positive CHMP opinion for adalimumab biosimilar CYLTEZO®September 15, 2017

    • Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cyltezo® (adalimumab biosimilar) for the treatment of multiple chronic inflammatory diseases
    • Recommendation based on extensive analytical, pharmacological, non –clinical & clinical data, which demonstrated similarity of Cyltezo® /BI 695501 to Humira®
    • Positive opinion follows the recent FDA approval of Cyltezo®1


    Continue Reading >
    Global Foundation Launches to Accelerate an End to SmokingSeptember 15, 2017

    Foundation for a Smoke-Free World Secures Major 12 Year Funding Commitment;

    Shares Initial Plans to Reduce Harm and Deaths from Smoking Worldwide

    (AETOS Wire)-- With the goal of eliminating smoking worldwide, the Foundation for a Smoke-Free World formally launched today in New York City. The Foundation is founded and led by Dr."...

    Continue Reading >
    Two New Innovative Swiss Made EDOF IOLs for Cataract SurgerySeptember 15, 2017

    (AETOS Wire)-- The company Swiss Advanced Vision (SAV-IOL SA) announced today the launch of LUCIDIS and EDEN, two new intraocular lenses (IOLs) for the cataract surgery, both using the Instant Focus EDOF patented technology. With a brand-new concept, LUCIDIS brings two major achievements for the monofocal market: extending the depth of focus on a monofocal lens while being the first affordable EDOF IOL. Thanks to its advanced refractive design, it allows an extension towards the near"...

    Continue Reading >
    Life Line Screening Expands Product Base to DNA, Clinical Trials September 13, 2017

    (AETOS Wire)-- Life Line Screening, a leader in community-based preventive healthcare, is deepening its delivery model of face-to-face patient care to provide access to advanced precision medicine through DNA testing and clinical trials.

    This expansion is a natural outcome of the company’s already rigorous research arm, which has resulted in dozens of papers and presentations that analyze the company’s"...

    Continue Reading >
    Kaneka Eurogentec Announces the Construction of a New Large Scale Pharmaceutical Grade Biologics Manufacturing FacilitySeptember 13, 2017

    (AETOS Wire)-- Kaneka Eurogentec, a custom service and FDA inspected contract development and manufacturing organization (CDMO), announced today that its board has approved the construction of a new state of-the-art GMP facility adjacent to its current facility and equipped with a 2200 L fermenter. The expansion will allow for the large scale production of biopharmaceuticals including recombinant proteins, antibody fragments and plasmid DNA.


    Continue Reading >